Ebenezer

NEW: OpenAI is the latest tech giant to move into biopharma, launching Thursday GPT-Rosalind, a life sciences-tailored version of its LLM Trails behind the very similar launch of Anthropic's Claude for Life Sciences by ~5 months. More here: endpoints.news/openai-launche…

This week's healthcare links and financings, in which I also opine on: mitochondrial replacement in AKI and CKD deanmarshallphd.substack.com/publish/post/1…

And I have to say, there’s a “founder friendly” fund that turned me down twice and I hear consistently that others have had not so great experiences, so I did it myself with CrossBridge to a great outcome. Won’t go into specifics but my academic co-founders own as much as me, all my R&D team did very well, my SAFE investors made 17x, my Seed investors made 10x, and it was 1.5 years from Seed to Series A. That’s how it’s supposed to be done. Win win for absolutely everyone. That’s what I’m most proud of actually. So for those founders and first time CEOs struggling, know it can be done, and know I’m happy to help in any way! And one other tidbit. I got an email from a fund two days before we closed that they’re passing on my Series A. Our last correspondence was Jan 28. So, be resilient my friends and keep building!

The Montreal Expos are exiting the baseball space. During Q2 and Q3 2026, we will transition to acquiring high-performance GPU assets. This is all part of our long-term vision to become a fully integrated GPU-as-a-Service (GPUaaS) and AI-native cloud solutions provider.

China Private Biotech Financing Tracker – 2026 Q1 Lead Asset landscape Development Stage Late‑stage (Phase 3 and marketed) assets, though fewer in number, absorbed a significant share of total capital, underlining investor preference for reduced technical and regulatory risk. Therapeutic Area Focus (Top 5 by Capital Raised) Oncology remained the dominant area by both deal count and total capital raised, while metabolism‑focused companies benefited from continued enthusiasm around obesity. Modality (Top 5 by Capital Raised) Small molecules continued to dominate overall capital intake, while cell therapy—particularly iPSC and CAR‑T approaches—remained an important focus area for strategic and state‑linked investors. x.com/chuminhua432/s…

Congrats @Mykalt45 ! businesswire.com/news/home/2026…

Related, a great post by the Bessemer folks outlining this landscape: x.com/i/status/20437…

🤦‍♂️ Intelligence AI, QuantHealth, Bullfrog AI already do this. Not to mention digital twins (Unlearn.AI, Aitia), trial design assists (Phesi, IQVIA, Citeline), and big guys with their own platforms (AZ, Insilico, BenevolentAI), most with years more clinical data

Should be required viewing for all nihilists. Lot of charlatans and frauds in the field, but so much more progress

Congrats to Gemini for winning Season 2 of EndPointArena.com! Season 3 starts will start Sunday in preparation for some big announcements Monday.

@bradloncar @daphnezohar Rockstar and legitimately nice person. Awesome to see

Congrats @daphnezohar!

This week's healthcare links and financings, in which I also opine on: the overuse of "first-in-class", especially when pitching generalists deanmarshallphd.substack.com/publish/post/1…

There is a hypothesis that birth order effects (on things like income and educational attainment) are in part respiratory pathogen effects: younger kids get more of them from their older siblings. This cool recent paper uses Danish administrative data to argue that this is true and a pretty large part of the story. (They claim 70% of the birth order effect on long-run wages.) Other work has previously shown that severe infections matter for long-run outcomes, and it's well-established that birth order matters, but I haven't until now seen anyone convincingly show that standard respiratory pathogens impose long-term costs on infant siblings. nber.org/system/files/w…

@bradloncar @endpointarena is the main guy

@BackwaterBio Who is behind this?

I think that one day soon that prediction markets are going to replace biotech stocks for how investors play key readouts...especially wrt larger companies. For example, if Novartis has a big phase 3, isn't it more interesting and efficient to play the event itself. Thoughts?

This week's healthcare links and financings, in which I also opine on: discussing the 129 tracked therapeutics financings in Q1 open.substack.com/pub/deanmarsha…

Heard joke once: VC goes to AI. Says he's confused. Says he doesn't understand startup pitch. Says he feels all alone in threatening world where what lies ahead is vague & uncertain. AI says, 'Simple. Invest if A16Z is investing.' VC bursts into tears. Says, 'But AI…I am A16Z.'

2Q26 Clinical $CYTK Afi nHCM ACACIA $RVMD Darax Ph2 2L+ PDAC data $ABVX Obe Ph3 UC Maintenance $VRDN ‘003 Ph3 Chronic TED $ALKS Lumryz Ph3 IH $MIRM Volixi Ph2 PSC $ADCT ZYN+RTX Ph3 2L+ DLBCL $APGE Zumi Ph2 AD Part B $SYRE SKYLINE Ph2 UC $INSM Brenso Ph2b HS $MBX Canvu Ph1/2 52W PTH $ALLO Cema-Cel Ph2 1L LBCL IA $CGEM CD19xCD3 Ph1 SLE SAD